PASTIC Dspace Repository

REVIEW Pharmacogenomic approaches in the treatment of breast cancer by tamoxifen

Show simple item record

dc.contributor.author Sidra Ameen
dc.contributor.author Muhammad Imran Qadir
dc.contributor.author Bashir Ahmad
dc.date.accessioned 2023-01-20T05:47:28Z
dc.date.available 2023-01-20T05:47:28Z
dc.date.issued 2012-04-28
dc.identifier.citation Ameen, S., Qadir, M. I., & Ahmad, B. (2012). Pharmacogenomic approaches in the treatment of breast cancer by tamoxifen. Pakistan journal of pharmaceutical sciences, 25(2). en_US
dc.identifier.issn 1011-601X
dc.identifier.uri http://142.54.178.187:9060/xmlui/handle/123456789/16205
dc.description.abstract Breast cancer (BC) is a highly diverse complaint rather than sole disease consisting of several markers linked to typical features of tissues, medical assessment and reaction to treatment. Mutation in RAS/MEK/ERK and PI3KAKT-mTOR pathway is involved in pathogenesis of BC. Application of pharmacogenomics will lead to individualization of therapy, which is totally contrast to nowadays clinical practice, in which drug’s effects are studied on large group of patient regardless of their genetic based difference. The genetic differences in persons affect the therapeutic action and concentration of Tamoxifen in each individual. Therefore, it is, concluded to choose best drug regimen for each patient on individual basis and to circumvent the patient by toxic effect of drug. en_US
dc.language.iso en en_US
dc.publisher Karachi: Faculty of Pharmacy & Pharmaceutical Sciences University of Karachi en_US
dc.subject Breast cancer en_US
dc.subject tamoxifen en_US
dc.subject pharmacogenomics en_US
dc.title REVIEW Pharmacogenomic approaches in the treatment of breast cancer by tamoxifen en_US
dc.type Article en_US


Files in this item

This item appears in the following Collection(s)

Show simple item record

Search DSpace


Advanced Search

Browse

My Account